Overview

Price chart · mood · technical indicators

NKTR

Nektar Therapeuticsstock Healthcare

Biotechnology

$86.89802.28%Current Market Mood:Strong Bullish

Market Mood

Price Range (1Y)

$7.99$109.00

Current: $86.89

Idea: EMA

1Y Return

+247.2%

Sharpe 3Y

0.70

Market Comparison

vs Healthcare Sector & Biotechnology Industry

NKTR

+802.28%

1Y Performance

Fundamentals

Updated daily after market close

P/E ratio—Forward 34.01

EPS (TTM)$-9.730.0% YoY

Profit margin-297.1%HEALTHCARE

Market cap$2.92BMid cap

Wall Street coverage

$144.25median target· current $24.75 (+482.8%)10 analysts

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

Valuation

Forward P/E: 34.01
PEG ratio: 0.31
P/B: 32.48
P/S (TTM): 52.82
EV/EBITDA: -6.50

Profitability & growth

ROE (TTM): -217.9%
Operating margin: -87.5%
Revenue growth YoY: -25.3%
Dividend yield: —
Beta: 1.18

Last earnings

Mar 13, 2026 · Estimate $-3.50 · Reported $-1.29

Analyst estimate. Actual results often differ.

Ratios are point-in-time. Historical metrics — no guarantees about what comes next.

News & Sentiment

50 articles · sorted by date

Page 1 of 3 · 50 total

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

About Nektar Therapeutics

Company profile

Nektar Therapeutics is a biopharmaceutical company. The company is headquartered in San Francisco, California with additional operations in Huntsville, Alabama and Hyderabad, India.

Classification

Sector: Healthcare
Industry: Biotechnology
Exchange: NASDAQ
Country: USA
Currency: USD

Company profile

HQ: 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA
Fiscal year end: December
Latest quarter: Dec 31, 2025

Market cap$2.92B

Shares outstanding$33.7M

52W high$109.00

52W low$7.99

Educational content · Not investment advice or recommendations

We're educators, not advisors. Your decisions are your own. Disclaimer

Overview

NKTR

Market Comparison

Fundamentals

Wall Street coverage

Valuation

Profitability & growth

News & Sentiment

NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm

A Look At Nektar Therapeutics (NKTR) Valuation After New REZOLVE AA Data Funding And Phase 3 Plans

Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nektar Therapeutics (NKTR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

Bronstein, Gewirtz & Grossman LLC Urges Nektar Therapeutics

NKTR UPCOMING DEADLINE : The Gross Law Firm Alerts Nektar Therapeutics Stockholders of Securities Class Action - Contact the Firm

NKTR UPCOMING DEADLINE : The Gross Law Firm Alerts Nektar Therapeutics Stockholders of Securities Class Action - Contact the Firm

NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm

Nektar Therapeutics (NKTR) Expected to Announce Quarterly Earnings on Thursday

Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics and Certain Officers - NKTR

NKTR INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026

United States - Goodwin Guides Nektar Therapeutics On Its $373.8 Million Underwritten Public Offering, Including Full Exercise Of Underwriters' Option To Purchase Additional Shares

NEKTAR THERAPEUTICS (NKTR) SHAREHOLDER ALERT - Bernstein

NKTR Investor Alert: Nektar Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Misrepresenting Trial Data Integrity: SueWallSt

SHAREHOLDER ALERT Securities Class Action Filed Against Nektar Therapeutics (NKTR)

NKTR Investor Alert: Nektar Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Zalevsky Allegedly Overstated Enrollment Compliance: Levi & Korsinsky

Why Nektar Therapeutics (NKTR) Is Down 8.6% After Raising Capital And Reporting New Alopecia Data

ROSEN, LEADING GLOBAL COUNSEL, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action- NKTR

Nektar sets May 7 earnings release, webcast starts 5 p.m. ET

About Nektar Therapeutics

Classification

Company profile

NKTR

Market Comparison

NKTR Market Analysis

Overview

NKTR

Market Comparison

Fundamentals

Wall Street coverage

Valuation

Profitability & growth

News & Sentiment

NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm

A Look At Nektar Therapeutics (NKTR) Valuation After New REZOLVE AA Data Funding And Phase 3 Plans

Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nektar Therapeutics (NKTR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

Bronstein, Gewirtz & Grossman LLC Urges Nektar Therapeutics

NKTR UPCOMING DEADLINE : The Gross Law Firm Alerts Nektar Therapeutics Stockholders of Securities Class Action - Contact the Firm

NKTR UPCOMING DEADLINE : The Gross Law Firm Alerts Nektar Therapeutics Stockholders of Securities Class Action - Contact the Firm

NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm

Nektar Therapeutics (NKTR) Expected to Announce Quarterly Earnings on Thursday

Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics and Certain Officers - NKTR

NKTR INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026

United States - Goodwin Guides Nektar Therapeutics On Its $373.8 Million Underwritten Public Offering, Including Full Exercise Of Underwriters' Option To Purchase Additional Shares

NEKTAR THERAPEUTICS (NKTR) SHAREHOLDER ALERT - Bernstein

NKTR Investor Alert: Nektar Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Misrepresenting Trial Data Integrity: SueWallSt

SHAREHOLDER ALERT Securities Class Action Filed Against Nektar Therapeutics (NKTR)

NKTR Investor Alert: Nektar Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Zalevsky Allegedly Overstated Enrollment Compliance: Levi & Korsinsky

Why Nektar Therapeutics (NKTR) Is Down 8.6% After Raising Capital And Reporting New Alopecia Data

ROSEN, LEADING GLOBAL COUNSEL, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action- NKTR

Nektar sets May 7 earnings release, webcast starts 5 p.m. ET

About Nektar Therapeutics

Classification

Company profile

NKTR

Market Comparison